Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 3/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | PPARG | P37231 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | FABP4 | P15090 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479725 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL12970667 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1242004 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL6382220 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1479722 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1476445 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL15902619 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL22607964 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL21214020 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL198434 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514932-B2 | PEG lipidoid compounds | TRANSLATE BIO, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12453759-B2 | Di-thioester cationic lipids | TRANSLATE BIO, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12377053-B2 | Cationic polymers | TRANSLATE BIO, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12280117-B2 | Lipid nanoparticle formulations for delivery of MRNA | TRANSLATE BIO, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250099384-A1 | THIOESTER CATIONIC LIPIDS | TRANSLATE BIO INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12257305-B2 | Cationic lipid compounds | TRANSLATE BIO, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240398720-A1 | CATIONIC POLYMERS | TRANSLATE BIO, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240374521-A1 | RIBOSE CATIONIC LIPIDS | TRANSLATE BIO INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240293319-A1 | Lipid Formulations for Delivery of Messenger RNA | TRANSLATE BIO, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-12076439-B2 | Thioester cationic lipids | TRANSLATE BIO, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20170314041-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | RANA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170281542-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-10-05 | — | — | US | disclosed |
| US-9629804-B2 | Lipid formulations for delivery of messenger RNA | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| EP-3105317-A1 | CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS | Cellectis (FR) | 2016-12-21 | — | — | EP | disclosed |
| EP-3060257-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | Shire Human Genetic Therapies, Inc. (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20160184458-A1 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2015121454-A1 | CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS | CELLECTIS (FR) | 2015-08-20 | — | — | WO | disclosed |
| US-20150157565-A1 | PULMONARY DELIVERY OF MRNA TO NON-LUNG TARGET CELLS | TRANSLATE BIO, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150140070-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | TRANSLATE BIO, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015061467-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170314041-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | NSUN3, TRDMT1, NSUN2 | OXER1 4569/4885LTB4R2 4740/4885MAPT 2097/4885 |
| US-20160184458-A1 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SYNCRIP, HNRNPAB, HNRNPA2B1 | OXER1 4649/4885LTB4R2 4159/4885MAPT 1036/4885 |
| US-20240374521-A1 | RIBOSE CATIONIC LIPIDS | RPIA, RRM2B, SARNP | OXER1 4125/4885LTB4R2 2256/4885MAPT 3969/4885 |
| US-12076439-B2 | Thioester cationic lipids | CETP, LYPLA2, LYPLA1 | OXER1 3854/4885LTB4R2 1685/4885MAPT 3823/4885 |
| US-12453759-B2 | Di-thioester cationic lipids | ACOT7, LYPLA2, LYPLA1 | OXER1 3749/4885LTB4R2 2282/4885MAPT 2073/4885 |
| US-20250099384-A1 | THIOESTER CATIONIC LIPIDS | CETP, LYPLA2, LYPLA1 | OXER1 3854/4885LTB4R2 1685/4885MAPT 3823/4885 |
| US-20170281542-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | RNMT, NSUN3, IGF2BP3 | OXER1 4091/4885LTB4R2 2637/4885MAPT 3982/4885 |
| US-12257305-B2 | Cationic lipid compounds | NPC1L1, NPC1, APMAP | OXER1 3895/4885LTB4R2 1714/4885MAPT 4055/4885 |
| US-12280117-B2 | Lipid nanoparticle formulations for delivery of MRNA | CETP, NPC1L1, LIPA | OXER1 2400/4885LTB4R2 2153/4885MAPT 2077/4885 |
| US-20240293319-A1 | Lipid Formulations for Delivery of Messenger RNA | RNMT, NSUN3, IGF2BP3 | OXER1 4091/4885LTB4R2 2637/4885MAPT 3982/4885 |
| US-20150140070-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | RNMT, NSUN3, IGF2BP3 | OXER1 4091/4885LTB4R2 2637/4885MAPT 3982/4885 |
| US-12377053-B2 | Cationic polymers | RNMT, POLRMT, PARG | OXER1 4760/4885LTB4R2 4030/4885MAPT 1382/4885 |
| US-20240398720-A1 | CATIONIC POLYMERS | RNMT, POLRMT, PARG | OXER1 4760/4885LTB4R2 4030/4885MAPT 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.